ClinicalTrials.gg
Active, not recruitingNCT06081673Updated Sep 30, 2026

Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC

A Phase 2 interventional study of Penpulimab injection and cisplatin in Head and Neck Squamous Cell Carcinoma, sponsored by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Phase 2, Interventional, and Treatment

How we know

Updated Sep 30, 2026Now Active, not recruitingStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Squamous Cell Carcinoma of Head and Neck by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University — 10 open to participants now, 12 under way, 4 of them phase 3. Squamous Cell Carcinoma of Head and Neck · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University.

Planned enrollment
11th of 19
72 · median 81
Started
2023
with 1 other
Phase 2
13 of 20
4 open now
Primary completion
2026-12
later than 3 of 11 live
Registered
11th of 20
by date

Among the 20 studies in Squamous Cell Carcinoma of Head and Neck by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, this one is the 11th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2023, is one of 13 in phase 2, reaches primary completion later than 3 of the 11 other live ones, and was the 11th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

10 of the 20 studies in Squamous Cell Carcinoma of Head and Neck by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Squamous Cell Carcinoma of Head and Neck by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, or all of them as a file.
02

Study summary

This study aims to observe and explore the efficacy and safety of Penpulimab combined with chemotherapy for neoadjuvant and adjuvant therapy in patients with resectable head and neck squamous cell carcinoma.

03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients voluntarily joined the study, signed the , and had good compliance;
  • Patients with 18 Years to 75 Years(at the time of signing the informed consent); Performance Status (ECOG-PS) score: 0-1;
  • Patients with untreated head and neck squamous cell carcinoma who were confirmed and determined to be suitable for surgical treatment were classified as stage III, IVa according to AJCC (8th Edition), including oral, oropharyngeal, hypopharyngeal, and laryngeal cancers
  • Female patients of reproductive age should agree that (such as intrauterine device, birth control pills, or condoms) must be used during the study period and for six months after completion; Having a negative serum pregnancy test within 7 days prior to study enrollment, and must be non-lactating; Male patients should agree to use contraception during the study period and for six months after the end of the study.

Exclusion criteria

Exclusion Criteria:

  • Patients who have previously used /PD-L1/CTLA-4 antibody therapy;
  • Patients who require systemic treatment with (> 10mg daily prednisone equivalent) or other drugs within 14 days prior to administration or during treatmentIn the absence of active disease, inhaled or topical steroids and adrenocortical hormone at doses >10mg/ day equivalent to prednisone and adrenocortical hormone replacement at therapeutic doses not exceeding 10mg/ day prednisone are permitted;
  • A history of any active immune or autoimmune disease, or a known history of allogeneic organ transplantation or hematopoietic stem cell transplantation;
  • Active or uncontrolled severe infection within 4 weeks prior to enrollment ( grade 2 infection);
  • Abnormal function of major organs
  • Patients with concomitant diseases that, in the investigator's judgment, may seriously endanger patients' safety or may interfere with the completion of the study, or are deemed unsuitable for inclusion for other reasons.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Penpulimab combined with cisplatin and albumin-paclitaxel neoadjuvant therapy

    Penpulimab injection combined with cis-platinum and albumin-bound paclitaxel before surgery, 21 days as a treatment cycle. Adjuvant therapy was started within 6 weeks after surgery:Patients who achieved MPR after surgery were randomized 1:1 with standard adjuvant therapy(RT alone or combined with cisplatin) and Alternative adjuvant therapy(RT alone or combined with Penpulimab). Non-MPR patients receive standard adjuvant therapy

    Drug: Penpulimab injection · Drug: cisplatin · Drug: albumin-paclitaxel

Interventions

  • DrugPenpulimabStudies of PenpulimabPenpulimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Penpulimab is a human immunoglobulin G1(IgG1) monoclonal antibody (mAb) directly programmed cell death-1 (PD-1). AK105 can effectively prevent human PD-1 binds to programmed cell death-1 ligand 1(PD-L1) and programmed cell death-1 ligand 2(PD-L2); 200mg,D1, IV(21 days/cycle).

  • Cisplatin :75mg/m2, D1, IV(21 days/cycle)

  • DrugAlbumin-Bound PaclitaxelStudies of Albumin-Bound PaclitaxelAlbumin-Bound Paclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    albumin-paclitaxel :260mg/m2,IVgtt,D1(21 days/cycle)

06

What researchers measure

Primary outcomes

  1. Major pathological response(MPR)

    Major pathologic response is based on the pathological examination on the post-operative specimens.

    Time frame: One year

Secondary outcomes

  1. Disease-control Rate(DCR)

    The proportion of subjects response of CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for ≥4 weeks).

    Time frame: Baseline up to 3 years.

  2. Adverse event rate

    The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).

    Time frame: Baseline up to 3 years.

  3. Disease-free survival at 2 years(DFS at 2 years)

    The proportion of subjects disease-free survival at 2 years

    Time frame: Baseline up to 2 years.

  4. Overall Response Rate (ORR)

    The proportion of subjects who achieves a best overall response of CR or PR.

    Time frame: Baseline up to 3 years.

  5. Local recurrence-free survival at 2years(LRFS at 2 years)

    The proportion of subjects local recurrence-free survival at 2years

    Time frame: Baseline up to 2 years.

  6. distant metastasis-free survival at 2 years(DMFS at 2 years)

    The proportion of subjects distant metastasis-free survival at 2years

    Time frame: Baseline up to 2 years.

  7. OS at 2 years

    The overall survival time refers to the time from initiating inductive therapy to death due to any cause.

    Time frame: Baseline up to 2 years.

  8. pathologic complete response(pCR)

    Pathological examination showed the presence of 0% active tumor in the tissue specimen

    Time frame: One year

07

Study locations

1 site
  • Shanghai Ninth People's Hostipal, Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality 200011, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2026, 38 months after the start.

Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's planned 38 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Dec 2024 → Dec 2026 and completion Oct 2026 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2023
First posted
Oct 13, 2023
StartActual
Oct 17, 2023
Primary completionEst.
Dec 30, 2026was Dec 2024
CompletionEst.
Oct 30, 2027was Oct 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Sep 30, 2026
Sites
1 site added, 1 site removed
Show site
  • Shanghai Ninth People's Hostipal, Shanghai Jiao Tong University School of Medicine · Shanghai, China
Show 1 removed
  • Shanghai Ninth People's Hostipal, Shanghai Jiao Tong University School of Medicine · Shanghai, China
Sep 30, 2026
Start date
Oct 30, 2023→Oct 17, 2023 (actual)
Sep 30, 2026
Primary completion
Dec 30, 2024→Dec 30, 2026
Sep 30, 2026
Study completion
Oct 30, 2026→Oct 30, 2027
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Recruiting→Active, not recruiting
    1 site added, 1 site removed
    Show site
    • Shanghai Ninth People's Hostipal, Shanghai Jiao Tong University School of Medicine · Shanghai, China
    Show 1 removed
    • Shanghai Ninth People's Hostipal, Shanghai Jiao Tong University School of Medicine · Shanghai, China
    Start date Oct 30, 2023→Oct 17, 2023 (now actual)
    Primary completion Dec 30, 2024→Dec 30, 2026
    Study completion Oct 30, 2026→Oct 30, 2027
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06081673
Responsible party
Sponsor
First posted
Oct 13, 2023
Start date
Oct 17, 2023
Primary completion
Dec 30, 2026 (estimated)
Completion
Oct 30, 2027 (estimated)
Last update
Sep 30, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Penpulimab

Start the discussion